From the report, I quote the authors 1:1
The current 2019-nCoV outbreak is moving rapidly , the cumulative number of confirmed cases in mainland China has reached 80151, with 47,204 (58.89 %) cured cases and 2943 (3.67 %) deaths as of 2-Mar-2020, and no specific drug has been discovered for Coronavirus Disease 2019 (COVID-19). However, a number of clinical practice results showed that traditional Chinese medicine (TCM) plays significant role in the treatment of COVID-19, bringing new hope for the prevention and control of COVID-19.
TCM has a long history and played an indispensable role in the prevention and treatment of several epidemic diseases. During the SARS epidemic in 2003, the intervention of TCM has also achieved remarkable therapeutic effect. During the treatment period of COVID-19, more than 3100 medical staff of TCM were dispatched to Hubei province, and TCM scheme was included in the guideline on diagnosis and treatment of COVID-19 , and TCM experts fully participate in the whole rescue process. The decoction, Chinese patent medicine, acupuncture and other characteristic therapy of TCM was comprehensively employed, mainly treated based on syndrome differentiation. Specific TCM wards were set up, and established the designated hospital, moreover, TCM team participates in treatment collectively. Currently, the total number of confirmed cases treated by TCM has reached 60,107 . In 102 cases of mild symptoms treated with TCM, [A] the clinical symptom disappearance time was shortened by 2 days, [B] the recovery time of body temperature was shortened by 1.7 days, the [C] average length of stay in hospital was shortened by 2.2 days, the [D] improvement rate of CT image was increased by 22 %, [E] the clinical cure rate was increased by 33 %, 27.4 % reduction in [F] the rate of common to severe cases and 70 % [G] increase in lymphocyte.3 In addition, in the treatment of severe patients with TCM, the average length of stay in hospital and the [H] time of nucleic acid turning negative has been shortened by more than 2 days.
Numbers 1-21 for ingredients added by reposter; also added in brackets the information found about the ingredients. It is clear from the description of the specific ingredients, herbs, roots etc., that they are well tested for fighting coughs, fever and lung issues. So exactly the issues that COVID-19 bring. A combination of these TCM is very likely to work!
From current treatment results, TCM based on an over-all symptoms of 2019-nCoV pneumonia patients, has suggested to prescribe prescription that are likely to be effective, such as qingfei paidu decoction (QPD), gancaoganjiang decoction, sheganmahuang decoction, qingfei touxie fuzheng recipe, etc. QPD which consisted of  Ephedrae Herba (Mormon tea herb),  Glycyrrhizae Radix (Liquorice root) et Rhizoma Praeprata cum Melle (Licorice (Baked)),  Armeniacae Semen Amarum (apricot kernel),  Gypsum Fibrosum (type of plaster stone),  Cinnamomi Ramulus (dry twig of Cinnamomum cassia Presl, a plant in the family Lauraceae),  Alismatis Rhizoma (dried tuber of Alisma orientalis (Sam.) Juzep. of the family Alismatacea),  Polyporus (a genus of poroid fungi in the family Polyporaceae),  Atractylodis Macrocephalae Rhizoma (rhizome of the perennial herbaceous plants Atractylodes macrocephala Koidz. of family Compositae),  Poria (type of mushroom long used in traditional Chinese medicine (TCM) as a medicinal tonic),  Bupleuri Radix (consists of the dried root of Bupleurum falcatum L. or B. falcatum L. var. scorzonerifolium (Willd.) Ledeb),  Scutellariae Radix (dried root of the medicinal plant Scutellariae baicalensis Georgi),  Pinelliae Rhizoma Praepratum cum Zingibere et Alumine (Raw Pinelliae Rhizoma (RPR) is a representative toxic herb that is widely used for eliminating phlegm or treating cough and vomiting. Given its irritant toxicity, its processed products, including Pinelliae Rhizoma Praeparatum (PRP) and Pinelliae Rhizoma Praeparatum cum Zingibere et Alumine (PRPZA), are more commonly applied and administered concomitantly with other chemical drugs, such as cough medications),  Zingiberis Rhizoma Recens (fresh rhizome of the Zingiberaceae plant ginger (Zingiber officinale Rosc)),  Asteris Radix et Rhizoma (the roots and rhizoma of Aster tataricus),  Farfarae Flos (The dry flower bud of perennial herb Tussilago farfara L. of family Composite.),  Belamcandae Rhizoma (derived from the rhizome of Belamcanda chinensis (L.)),  Asari Radix et Rhizoma (Xixin, Manchurian Wildginger, Asarum spp),  Dioscoreae Rhizoma (the dried rhizome of Dioscorea opposita Thunb),  Aurantii Fructus Immaturus (the dry fruit of Citrus aurantium L. and Citrus sinensis Osbeck),  Citri Reticulatae Pericarpium (an orange-colored Citrus reticulata Blanco fruit peel), and  Pogostemonis Herba (aerial part of perennial herbaceous plant Pogostemon cablin (Blanco) Benth), has been promoted as a general prescription in the diagnosis and treatment plan of COVID-19 in China .
Among the 701 confirmed cases treated by QPD, 130 cases were cured and discharged, clinical symptoms of 51 cases disappeared, 268 cases of symptoms improved, and 212 cases of stable symptoms without aggravation . The effective cure rate of QPD against COVID-19 is over 90 %. According to the theory of TCM, the target organ location of COVID-19 is the lung, and the etiology attribute is “damp and toxin plague”. The network pharmacology analysis showed that QPD has an overall regulatory effect via multi-component and multi-target. The primary site of pharmacological action is the lung, as 16 herbs to lung meridian, which indicated that the decoction is mainly specific for lung diseases. In addition, it can play the role of dehumidification through the rise and fall of the spleen and stomach, and exhibited the protection for heart, kidney and other organs. Among the potential targets screen, most of them co-expressed with ACE-2, the receptor of COVID-19, indicating the potential improvement of COVID-19. It can inhibit the replication of COVID-19 by acting on multiple ribosomal proteins. COVID-19 can lead to strong immune response and inflammatory storm . Functional enrichment analysis showed that QPD could inhibit and alleviate excessive immune response and eliminate inflammation by regulating immune related pathway and cytokine action related pathway . Furthermore, through the prediction of molecular docking, it was found that patchouli alcohol, ergosterol and shionone in the formula had better anti−COVID-19 effect, which provided new molecule structures for new drug development .
Here, we take one highly suspected COVID-19 patient treated with TCM as a case example to show its effectiveness . The male patient was on a business trip in Wuhan for several days before the onset of the disease. During the admission period, fever and cough were repeated, and respiratory rales of both lungs were not obvious. Western medicine was used firstly, including orally take oseltamivir phosphate capsule, intravenous infusion of ganciclovir, aerosol inhalation of recombinant human interferon a1b, etc. Although the nucleic acid test was negative, the results of chest CT showed that the fusion of two lung ground glass shadows was enlarged and the density was increased, which was more advanced than that of admission (Fig. 1a-1c). As the serious illness, combined with the patient’s performance of damp-heat syndrome, and the heat is more serious than damp, QPD was added for treatment. On the night of administration, the body temperature dropped to 36.2 ℃, and then tended to be normal. After 6 days of treatment, chest CT was better than before, tracheobronchial shadow was normal, and inflammation was obviously absorbed (Fig. 1d). The patient had no fever or asthenia, coughing occasionally, and the rales of two lungs were weaker than before. After discharge, continue to take 7 doses of the prescription, occasionally cough, no special discomfort was found. The clinical symptoms and imaging examination of the patients improved significantly after the treatment, reflecting the advantages of TCM.
Traditional Chinese medicine for COVID-19 treatment
Jun-ling Ren Ai-HuaZhang Xi-JunWang
Volume 155, May 2020, 104743